ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

12-Nov-2020

MarketWatch news site noted Noxopharm’s pilot study in cancer patients with Bristol Myers Squibb;

Click here to read more

Note: MarketWatch News Department was not involved in the creation of this content


12-Nov-2020

Digital stock market news site, TD Ameritrade posted: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

12-Nov-2020

BioSpace, the Life Science industry digital news and information source reported, “Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product”

Click here to read more

12-Nov-2020

BioWorld, in its Other News to Note section said,” Noxopharm Ltd., of Sydney, is partnering with Bristol Myers Squibb Co., of New York, to study Noxopharm's sphingosine-1-phosphate inhibitor, Veyonda, in cancer patients who have developed a resistance to BMS’ Opdivo (nivolumab). The study, called Iconic-1, will start recruiting patients early in 2021.”

Click here to read more

12-Nov-2020

In relation to Noxopharm’s announcement, a digital news site to the pharmaceutical industry, FirstWord Pharma, reported the following

Click here to read more

12-Nov-2020

PharmaVoice, “a resource for life-sciences executives and other healthcare-service related professionals” posted the following News Release; Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

Click here to read more

10-Nov-2020

BiotechDispatch, a site dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector reported

9-Oct-2020

Pharmaceutical Business Review wrote," As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company's Phase 1 NOXCOVID-1 study.

Click here to read more

8-Oct-2020

PharmaVOICE.com  A US industry digital news website said," NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more